Spots Global Cancer Trial Database for accelerated phase chronic myelogenous leukemia
Every month we try and update this database with for accelerated phase chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002800 | Leukemia Myelodysplastic... Neutropenia | filgrastim lintuzumab cytarabine etoposide idarubicin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia | NCT00002693 | Leukemia Neutropenia | filgrastim carboplatin topotecan hydro... | 18 Years - | Mayo Clinic | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia | NCT00006052 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | NCT01426334 | Accelerated Pha... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | dasatinib diagnostic labo... pharmacological... cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia | NCT00005986 | Leukemia | busulfan cyclophosphamid... filgrastim recombinant int... in vitro-treate... peripheral bloo... radiation thera... | 18 Years - 65 Years | Masonic Cancer Center, University of Minnesota | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia | NCT00002831 | Leukemia | Filgrastim Busulfan Cyclophosphamid... Cyclosporine Decitabine (DAC... Methotrexate Methylprednisol... Tacrolimus Allogeneic Bone... Peripheral Bloo... | 15 Years - 55 Years | M.D. Anderson Cancer Center | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Natural History Study of Patients With Chronic Myelogenous Leukemia | NCT00429910 | Leukemia | 18 Years - 120 Years | Dana-Farber Cancer Institute | ||
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00054431 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... decitabine laboratory biom... | - | National Cancer Institute (NCI) | |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00101088 | Accelerated Pha... Blastic Phase C... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | imatinib mesyla... temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Bone Marrow Transplantation in Treating Patients With Leukemia | NCT00006451 | Graft Versus Ho... Leukemia Lymphoma | anti-thymocyte ... cyclophosphamid... cyclosporine methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia | NCT00004878 | Graft Versus Ho... Leukemia | therapeutic all... cytarabine fludarabine pho... idarubicin methotrexate tacrolimus in vitro-treate... peripheral bloo... | 50 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | NCT00052598 | Accelerated Pha... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Chron... Childhood Myelo... Recurrent Adult... Recurrent Child... Relapsing Chron... Secondary Acute... | therapeutic all... aldesleukin laboratory biom... flow cytometry | - | Fred Hutchinson Cancer Center | |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | NCT00066326 | Leukemia | imatinib mesyla... tanespimycin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00345826 | Leukemia | dasatinib | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia | NCT00002789 | Leukemia | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | 15 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00816283 | Leukemia | dasatinib vorinostat cytogenetic ana... gene expression... mutation analys... reverse transcr... flow cytometry laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia | NCT00005986 | Leukemia | busulfan cyclophosphamid... filgrastim recombinant int... in vitro-treate... peripheral bloo... radiation thera... | 18 Years - 65 Years | Masonic Cancer Center, University of Minnesota | |
| Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | NCT00004065 | Bladder Cancer Breast Cancer Colorectal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Lung Cancer Melanoma (Skin) Ovarian Cancer Prostate Cancer Unspecified Adu... | tanespimycin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | NCT00098423 | Accelerated Pha... Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | tanespimycin cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00004918 | Accelerated Pha... Adult Acute Mye... Chronic Phase C... Previously Trea... Refractory Anem... Refractory Anem... Relapsing Chron... | PR1 leukemia pe... Montanide ISA 5... sargramostim laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | NCT00860574 | Accelerated Pha... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Secondary Myelo... Untreated Adult... Untreated Child... | treosulfan fludarabine pho... total-body irra... peripheral bloo... tacrolimus allogeneic bone... allogeneic hema... methotrexate | - 60 Years | Fred Hutchinson Cancer Center | |
| Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002778 | Leukemia | sargramostim therapeutic all... allogeneic bone... in vitro-treate... | 18 Years - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | NCT00004009 | Leukemia | tipifarnib | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | NCT00316953 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Meningeal Chron... Recurrent Child... Relapsing Chron... Unspecified Chi... | dasatinib pharmacological... laboratory biom... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002592 | Leukemia | c-myb antisense... filgrastim busulfan cyclophosphamid... autologous bone... in vitro-treate... | 18 Years - 60 Years | Abramson Cancer Center at Penn Medicine | |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | NCT00005854 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | cyclophosphamid... cyclosporine methotrexate allogeneic bone... in vitro-treate... radiation thera... | - 50 Years | Fred Hutchinson Cancer Center | |
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | NCT00816413 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... Nonmalignant Ne... | cyclosporine mycophenolate m... pentostatin cytogenetic ana... fluorescence in... protein analysi... flow cytometry immunoenzyme te... laboratory biom... reduced-intensi... nonmyeloablativ... peripheral bloo... total-body irra... | 19 Years - 75 Years | University of Nebraska | |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis | NCT00387426 | Accelerated Pha... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Mast Cell Leuke... Meningeal Chron... Primary Myelofi... Progressive Hai... Prolymphocytic ... Recurrent Adult... Recurrent Adult... Refractory Chro... Refractory Hair... Relapsing Chron... Secondary Acute... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... T-cell Large Gr... Untreated Adult... Untreated Adult... Untreated Hairy... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia | NCT00002789 | Leukemia | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | 15 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease | NCT00392782 | Leukemia Myelodysplastic... | anti-thymocyte ... fludarabine pho... thiotepa peripheral bloo... total-body irra... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | NCT00006350 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | daclizumab therapeutic all... mycophenolate m... tacrolimus peripheral bloo... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | NCT00004145 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 60 Years | University of Chicago | |
| PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy | NCT00335868 | Leukemia | danusertib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
